Concise Review: Stem Cell-Based Treatment of Pelizaeus-Merzbacher Disease
Research output: Contribution to journal › Review › Research › peer-review
Standard
Concise Review : Stem Cell-Based Treatment of Pelizaeus-Merzbacher Disease. / Osorio, M. Joana; Rowitch, David H.; Tesar, Paul; Wernig, Marius; Windrem, Martha S.; Goldman, Steven A.
In: Stem Cells, Vol. 35, No. 2, 02.2017, p. 311-315.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Concise Review
T2 - Stem Cell-Based Treatment of Pelizaeus-Merzbacher Disease
AU - Osorio, M. Joana
AU - Rowitch, David H.
AU - Tesar, Paul
AU - Wernig, Marius
AU - Windrem, Martha S.
AU - Goldman, Steven A.
N1 - © 2016 AlphaMed Press.
PY - 2017/2
Y1 - 2017/2
N2 - Pelizaeus-Merzbacher disease (PMD) is an X-linked disorder caused by mutation in the proteolipid protein-1 (PLP1) gene, which encodes the proteolipid protein of myelinating oligodendroglia. PMD exhibits phenotypic variability that reflects its considerable genotypic heterogeneity, but all forms of the disease result in central hypomyelination, associated in most cases with early neurological dysfunction, progressive deterioration, and ultimately death. PMD may present as a connatal, classic and transitional forms, or as the less severe spastic paraplegia type 2 and PLP-null phenotypes. These disorders are most often associated with duplications of the PLP1 gene, but can also be caused by coding and noncoding point mutations as well as full or partial deletion of the gene. A number of genetically-distinct but phenotypically-similar disorders of hypomyelination exist which, like PMD, lack any effective therapy. Yet as relatively pure CNS hypomyelinating disorders, with limited involvement of the PNS and relatively little attendant neuronal pathology, PMD and similar hypomyelinating disorders are attractive therapeutic targets for neural stem cell and glial progenitor cell transplantation, efforts at which are now underway in a number of research centers.
AB - Pelizaeus-Merzbacher disease (PMD) is an X-linked disorder caused by mutation in the proteolipid protein-1 (PLP1) gene, which encodes the proteolipid protein of myelinating oligodendroglia. PMD exhibits phenotypic variability that reflects its considerable genotypic heterogeneity, but all forms of the disease result in central hypomyelination, associated in most cases with early neurological dysfunction, progressive deterioration, and ultimately death. PMD may present as a connatal, classic and transitional forms, or as the less severe spastic paraplegia type 2 and PLP-null phenotypes. These disorders are most often associated with duplications of the PLP1 gene, but can also be caused by coding and noncoding point mutations as well as full or partial deletion of the gene. A number of genetically-distinct but phenotypically-similar disorders of hypomyelination exist which, like PMD, lack any effective therapy. Yet as relatively pure CNS hypomyelinating disorders, with limited involvement of the PNS and relatively little attendant neuronal pathology, PMD and similar hypomyelinating disorders are attractive therapeutic targets for neural stem cell and glial progenitor cell transplantation, efforts at which are now underway in a number of research centers.
KW - Journal Article
KW - Review
U2 - 10.1002/stem.2530
DO - 10.1002/stem.2530
M3 - Review
C2 - 27882623
VL - 35
SP - 311
EP - 315
JO - Stem Cells
JF - Stem Cells
SN - 1066-5099
IS - 2
ER -
ID: 185946811